ClinicalTrials.gg
CompletedNCT05213585Updated Sep 24, 2026

Treatment of Ocular Demodex Infestation With Topical Ivermectin Cream 1%

A Phase 3 interventional study of Ivermectin 1% cream in The Focus of the Study is to Assess the Effectiveness of Topical Ivermectin on Eliminating Eyelash Sleeves, sponsored by Helm Vision Group. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Helm Vision Group · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.
  • Registered 4 months after the study started (first participant enrolled Aug 2021, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Patients with Demodex infestation of the eyelids will have the sleeves from both eyes cleaned off with microblepharoexfoliation. Afterwards, one eye will be randomly selected for treatment with topical ivermectin 1% cream. The treatment will be repeated on that eye 2 weeks later. Afterwards, participants will present monthly for photographs of the eyelashes. The photographs will be reviewed by an ophthalmologist outside of the study site who will be blind to which eye was treated and independently grade the amount of sleeves in each eye. The follow-up will be for 6 months after the second treatment for Group A eyes. At the 6 months point the second phase of the study will begin by treating the control eyes (now called Group B eyes) with a single application of ivermectin cream and no pre-treatment with microblepharoexfoliation.

Read the detailed description

Informed Consent Form and Authorization to Use and Disclose Protected Health Information

Sponsor / Study Title:

Helm Vision Group / "Treatment of Ocular Demodex Infestation with Topical Ivermectin Cream"

Principal Investigator:

(Study Doctor) Craig Helm, MD

Telephone:

661-259-3937 (24 Hours)

Address: Helm Vision Group 27420 Tourney Rd. Suite 100 Valencia, CA 91355

Background and Purpose

Participants are being recruited to participate in this research study who have been found to have an overgrowth of the eyelash mite (Demodex folliculorum). The investigators expect to enroll 20 subjects in this study.

Mites are small arthropods. Two of these species of mites are specific to humans and are named Demodex folliculorum and Demodex brevis. Demodex folliculorum lives within human hair follicles, whereas Demodex brevis lives in human sebaceous glands.

It is not clearly understood how people get mites but the older one gets the more likely it is that mites will be present. Demodex mites have been determined to be a source of eye and eyelid problems for people of all ages, including children. Having Demodex overgrowth is not a result of poor hygiene. Normal face washing and even the use of baby shampoo lid scrubs do not kill the mites. Ultimately it is thought that everyone gets them, although not everyone seems to be bothered by them. However, they are a cause of suffering for many people.

The presence of Demodex mites is can cause of chronic eyelid inflammation (blepharitis) as well as styes and chalazia (small lumps or cysts within the eyelid). Symptoms of blepharitis include eyelid irritation, redness and itching. Demodex may also be a cause of dry eye syndrome.

The most commonly accepted treatment for eyelash mites involves the use of tea tree oil along the eyelash margin. This treatment though helpful does not usually result in elimination of the organism and can be very irritating depending upon the concentration of tea tree oil that is used. It is known that tea tree oil concentrations of at least 50% are required to kill the mites. Lower concentrations of tea tree oil are commercially available in eyelid wipes and may help to control the mite population but are insufficient to eradicate them.

The purpose of this study is to evaluate the effectiveness of ivermectin cream 1% in eliminating the presence of Demodex infestation of the eyelash follicles. A secondary goal is to evaluate the effectiveness of ivermectin cream 1% in reducing the symptoms of dry eye if any.

A third goal is to determine if study treatment with ivermectin 1% topical cream decreases the salinity of the tears.

Ivermectin cream is FDA-approved for use in rosacea which is a common skin condition associated with redness that affects the face and upper chest. However, the FDA has not approved the use of ivermectin cream for the use of treating Demodex infestation of the eyelids. Therefore, the use of ivermectin cream in this study is investigational.

What Will Happen During the Study?

The study will randomly select one eye to be treated with anti-Demodex study treatment while the other eye will be designated as a control eye and will not be treated with the study treatment.

Both eyes will have the eyelashes cleaned by microblepharoexfoliation (Blephex©). Blephex© is a treatment that uses a soft rotating foam brush soaked in a cleaning solution to remove the scale build-up along the eyelash margins. This build-up (or "biofilm") can constrict the opening of the oil glands (Meibomian glands) that are most important in lubricating the ocular (eye) surface. The Blephex© treatment also removes the debris left behind by the Demodex mites that encircles the base of the eyelashes which are infested. The Blephex procedure is performed after instilling a drop of anesthetic into the eyes. Each eyelid margin is then treated at the base of the eyelashes and lid margin to remove the scaly buildup along the lid margin and to remove the eyelash debris. The procedure takes less than 10 minutes to perform.

Those eyes randomized to the study treatment group will then have the ivermectin cream 1% applied to the base of the eyelashes, eyelids and surrounding skin. The cream will be left in place for 10 to 15 minutes after which point the excess cream will be wiped from the lashes with a saline soaked gauze pad.

At the initial or "baseline" visit each subject will complete a questionnaire which asks questions regarding dry eye and blepharitis symptoms.

A TearLab® test will be performed to measure the level of tear saltiness. The TearLab® test involves taking a tiny sample of tears from each eye and using a machine to analyze it and determine the salt content. This is used as a measure of the degree of dryness of the eyes. The test is painless.

Photographs of the eyelashes of all four eyelids will then be taken to document the extent of the mite infestation of the eyelids. Mites often leave debris at the base of eyelashes. This debris is called "cylindrical dandruff" or "sleeves." Next, a Blephex© treatment will be performed to remove all of the debris that the mites leave around the eyelashes. Repeat photographs will then be taken to document the successful removal of the mite debris. Afterwards, subjects will be randomized into either the study treatment group or the control group.

Study Treatment Group: Blephex© and study treatment with ivermectin 1% cream Control Group: Blephex© only.

Subjects in the study treatment group will return 2 weeks later for a second application of ivermectin 1% cream.

Photographs, TearLab® tests and the dry eye questionnaire will be repeated at the 2-week and monthly intervals from the date of study treatment for 6 months.

The study will end after 6 months. At this point the control eye will be treated and both eyes treated if necessary.

Risks, Side Effects, and/or Discomforts

Ivermectin

Ivermectin is a drug that has been in worldwide use since 1981 and has proven to be generally very safe. It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.

We are using ivermectin cream to avoid the risks associated with its oral use. However it is important that the participant is aware of all risks associated with ivermectin.

Although oral ivermectin is considered to be safe, a single case of ivermectin-induced severe hepatitis was reported in Switzerland in 2006 using a single dose of 15 mg.

The use of oral ivermectin has been also associated with the following side effects:

  • Fatigue (0.9% of subjects)
  • Abdominal pain (0.9%)
  • Anorexia (0.9%)
  • Constipation (0.9%)
  • Diarrhea (1.8%)
  • Nausea (1.8%)
  • Vomiting (0.9%)
  • Dizziness (2.8%)
  • Sleepiness (0.9%)
  • Vertigo (0.9%)
  • Tremors (0.9%)
  • Itching (2.8%)
  • Rash (0.9%)
  • Hives (0.9%)
  • Low white blood cell count (3%)
  • Elevated liver enzymes (2%)
  • Anemia

It has also been reported that ivermectin can increase the effect of warfarin (blood thinners, such as Coumadin) when used together.

The use of ivermectin cream has been associated with:

  • Burning
  • Itching
  • Redness
  • Stinging of the skin and eyes.

In this study we will apply the ivermectin cream around the eyelids and leave it in place for 10 to 15 minutes. After this period we will remove the excess cream. In our experience to date we have had subjects experience ocular burning and temporary blurring of vision but no other side effects. The blurring of vision has been temporary and in no case interfered with safe driving.

It is possible to have an allergic reaction of the skin to the ivermectin cream although we have not observed this. Absorption of the ivermectin into the body is assumed to be minimal.

BlephEx© A tickling sensation may be felt during the procedure. The eyelid skin may be somewhat irritated afterwards for an hour or two.

Unforeseen Risks

Since the use of the study treatment is investigational, there may be other risks that are unknown. Additionally, there may be unknown risks to a pregnancy, embryo, or fetus if a participant becomes pregnant.

Study Expectations

Participants will be enrolled in the study for a 180-day period. During the study period, participants will be asked to refrain from using any other type of medicated pad to clean the eyelids and will not be allowed to use any product containing tea tree oil, including tea tree oil-containing soap on the face. Any prescribed glaucoma drops may be used as there are no anti-Demodex properties known with these medications. Antibiotic drops or steroid drops may be prescribed for other ocular conditions as the need arises and will not exclude participation in this study.

Alternatives to Participation

It is not required to be in this study to receive treatment for this condition. Please talk to the study doctor about available options before deciding whether or not to take part in this study.

New Findings

Any new information that is discovered during the study which may influence a participant's willingness to continue in the study will be promptly disclosed.

Benefits

A participant may benefit as a result of being in this study. There is, however, no guarantee that a participant will benefit. However, information learned from the study may help other people in the future.

Compensation for Participation

Participants will not receive any monetary compensation for participation in this study.

Confidentiality

Records of participation in this study will be held confidential except when sharing the information required by law or as described in this informed consent. The Investigator, the sponsor or persons working on behalf of the sponsor, and under certain circumstances, the United States Food and Drug Administration (FDA) and the Institutional Review Board (IRB) will be able to inspect and copy confidential study-related records which identify participants by name. This means that absolute confidentiality cannot be guaranteed. If the results of this study are published or presented at meetings, participants will not be identified.

Compensation for Injury

If a participant becomes ill or are injured while in the study, get the needed medical care need right away. Study participants should inform the treating healthcare professional regarding this study. Participants should also inform the study staff regarding potentially related illness or injury to help the participant get needed care.

If a participant is injured as a result of taking the study drug(s) or from procedures done for the purpose of this study, the sponsor will pay for those medical expenses necessary to treat any injury that is not covered by the participant's medical insurance or any other third-party coverage. By signing and dating this document, the participant will not lose any legal rights or release anyone involved in the research from responsibility for mistakes.

Costs

The participant will be charged the usual and customary charges for office visits and photography as per the contracted rate with the participant's insurance company. There will be no charge to the participant for the Blephex treatment or application of the ivermectin cream.

Whom to Contact About this Study

If during the study, the participant experiences any medical problems, suffers a research-related injury, or has questions, concerns or complaints about the study, the participant should contact the study doctor at the telephone number listed on the first page of this consent document. If the participant seeks emergency care, or hospitalization is required, the treating physician should be made aware of the participant's involvement in this research study.

An institutional review board (IRB) is an independent committee established to help protect the rights of research subjects. If the participant has any questions regarding rights as a research subject, and/or concerns or complaints regarding this research study, contact:

  • By mail: Study Subject Adviser Advarra IRB 6940 Columbia Gateway Drive, Suite 110 Columbia, MD 21046
  • or call toll free: 877-992-4724
  • or by email: adviser@advarra.com

Please reference the following number when contacting the Study Subject Adviser: Pro00044340.

Voluntary Participation / Withdrawal

Participation in this study is voluntary. The participant may choose to not participate or or y withdraw from the study for any reason without penalty or loss of benefits to which the participant is otherwise entitled and without any effect on on the future medical care of the participant. However, please note that the FDA requires that any information collected up to the point of withdrawal cannot be removed from the study.

The study doctor or the sponsor can stop dis-enroll a participant from the study at any time without consent for the following reasons:

  • If it appears to be medically harmful to the participant;
  • If the participant fails to follow directions for participating in the study;
  • If it is discovered that the participant does not meet the study requirements;
  • If the study is canceled; or
  • For administrative reasons.

If a participant leaves the study for any reason, the study doctor may ask the participant to have some end-of-study tests for the participant's safety.

Acknowledgment and Consent

The purpose, goals, expectations and risks of this study have been adequately explained to me. I hereby give my consent to be enrolled. I understand that enrollment is completely voluntary and that no proven available treatment will be withheld from me if I decided not to enroll in the study. I understand that I may withdraw from participation this study at any time without any penalty. I understand that my authorization and consent to use my information expires at the end of this research study. The information gathered from this study is considered protected health information and that information which is presented in scientific meetings or published in the medical literature will not include my name or any information that identifies me to anyone hearing or reading the report.

_________________________ Subject's Printed Name

  • _________________________ _________________________ Subject's Signature Date

Printed Name of Person Conducting the Consent Discussion

_________________________ _________________________ Signature of the Person Conducting Date the Consent Discussion

AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH INFORMATION

With participation in this study, the study doctor and study staff will use and share health data about the participant to conduct the study. Health data may include:

  • Participant's name.
  • Address.
  • Phone number.
  • Date of birth.
  • Medical history.
  • Information from the participant's study visits, including all test results.

Health data may come from the participant's study records or from existing records kept by the participant's doctor or other health care workers.

For this study, the study staff may share health data about the participant with authorized users. Authorized users may include:

  • Representatives of Helm Vision Group.
  • Representatives of Advarra IRB (an Institutional Review Board that reviews this study).
  • The Food and Drug Administration (FDA) and other US federal and state agencies.
  • Government agencies to whom certain diseases (like HIV, hepatitis, and STDs) must be reported.
  • Governmental agencies of other countries.
  • Outside individuals and companies, such as laboratories and data storage companies, that work with the researchers and sponsor and need to access the participant's information to conduct this study.
  • Other research doctors and medical centers participating in this study, if applicable.
  • A data safety monitoring board which oversees this study, if applicable.

The participant's health data will be used to conduct and oversee the research, including for instance:

  • To see if the study treatment works and is safe.
  • To compare the study treatment to other treatments.
  • For other research activities related to the study treatment.

Once the participant's health data has been shared with authorized users, it may no longer be protected by federal privacy law and could possibly be used or disclosed in ways other than those listed here.

The participant's permission to use and share health data will end in 50 years unless the participant revokes it (take it back) sooner.

The participant may revoke (take back) permission to use and share health data about at any time by writing to the study doctor at the address listed on the first page of this form. Doing so would preclude the participant's ability to remain in this study. No new health data that identifies the participant will be gathered after written request is received. However, health data about the participant that has already been gathered may still be used and given to others as described in this form.

The right of the participant to access personal health data in the study records will be suspended during the study to keep from changing the study results. When the study is over, the participant can access personal study health data.

Signing and date this form is required for participation in the study.

02

Conditions studied

  • The Focus of the Study is to Assess the Effectiveness of Topical Ivermectin on Eliminating Eyelash Sleeves
03

In context

Lead sponsor

Helm Vision Group is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Able to provide Moderate to dense sleeves No allergy to ivermectin Able to keep follow-up appointments

Exclusion criteria

Exclusion Criteria:

Patients under 18 years old Allergy to ivermectin Inability to keep follow-up appointments

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Group A eyes

    All participants will have one eye randomly selected for treatment after performing microblepharoexfoliation on both eye. After 2 weeks, a second application of ivermectin cream will be applied to the same previously treated eye.

    Drug: Ivermectin 1% cream

  • Active comparator
    Group B eyes

    Group B eyes, which served as controls for the first 6 months of the study, will be treated with a single application of topical ivermectin cream without repeating the microblepharoexfoliation performed 6 months earlier.

    Drug: Ivermectin 1% cream

Interventions

  • DrugIvermectinStudies of IvermectinIvermectin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Both Group A and Group B eyes (from same patient) will be treated with microblepharoexfoliation. Afterwards, eyes randomly selected by computer will be assigned to Group A treatment eyes and the fellow eyes will be assigned to Group B. Group A eyes will receive an application of topical ivermectin 1% cream to the eyelids. This will be repeated 2 weeks later. Group B eyes will not receive treatment and serve as controls. After 6 months, Group B eyes will receive a single application of ivermectin 1% cream without repeating the microblepharoexfoliation that was done 6 months earlier. Both Group A and Group B eyes will be followed for an additional 6 months with assessment visits at 9 months and 12 months.

06

What researchers measure

Primary outcomes

  1. Comparative density of sleeves

    The density of sleeves will be clinically assessed and graded by the outcomes assessor

    Time frame: Each patient will be followed for 6 months.

Secondary outcomes

  1. Comparative assessment of tear osmolarity between treated and untreated eyes

    The tear osmolarity will be tested in each eye at each follow-up visit

    Time frame: Each patient will be followed for 6 months

  2. Modified SPEED Survey

    This is a subjective survey of dry eye symptoms. The Standard Patient Evaluation of Eye Dryness (SPEED) was modified to include fluctuating vision as a symptom.

    Time frame: From enrollment to the end of the follow-up 12 months after initiating treatment

07

Study locations

1 site
  • Helm Vision Group
    Santa Clarita, California 91355, United States
08

References and documents

Publications

  • Choi Y, Eom Y, Yoon EG, Song JS, Kim IH, Kim HM. Efficacy of Topical Ivermectin 1% in the Treatment of Demodex Blepharitis. Cornea. 2022 Apr 1;41(4):427-434. doi: 10.1097/ICO.0000000000002802. PubMed 34173370 ↗

Individual participant data

Plan to share: Yes — We can share the sleeve grading data, as well as the secondary outcome data: tear osmolarity and modified SPEED survey results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: October 2026 through September 2029

Access criteria: Interested researchers may reach out to the primary investigator at craighelm@sbcglobal.net

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Dec 2023, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2022
First posted
Jan 28, 2022
StartActual
Aug 24, 2021
Primary completionActual
Dec 31, 2023
CompletionActual
Dec 31, 2023
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05213585
Lead sponsor
Helm Vision Group
Responsible party
Craig J. Helm (Physician, Helm Vision Group) — Principal investigator
First posted
Jan 28, 2022
Start date
Aug 24, 2021
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Last update
Sep 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion